For research use only. Not for therapeutic Use.
NZ-419 (CAT: I008391), also referred to as HD003, is a promising compound recognized for its antioxidant properties, which make it a potential candidate for the treatment of renal failure. Renal failure involves the dysfunction or damage of the kidneys, often associated with oxidative stress and inflammation. NZ-419’s antioxidant activity suggests its potential to counteract oxidative damage and reduce inflammation in kidney cells, which could contribute to preserving renal function and mitigating the progression of renal failure.
| Catalog Number | I008391 |
| CAS Number | 84210-26-4 |
| Synonyms | NZ-419; HD-003; NZ 419; HD 003; NZ419; HD003;1-methylimidazolidine-2,4-dione |
| Molecular Formula | C4H6N2O3 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 5-hydroxy-1-methylimidazolidine-2,4-dione |
| InChI | InChI=1S/C4H6N2O3/c1-6-3(8)2(7)5-4(6)9/h3,8H,1H3,(H,5,7,9) |
| InChIKey | UPSFNXFLBMJUQW-UHFFFAOYSA-N |
| SMILES | CN1C(C(=O)NC1=O)O |
| Reference | </br>1:Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells. Ienaga K, Sohn M, Naiki M, Jaffa AA.J Recept Signal Transduct Res. 2014 Jun;34(3):195-200. doi: 10.3109/10799893.2013.876039. Epub 2014 Mar 18. PMID: 24641698 </br>2:Protective effect of an intrinsic antioxidant, HMH (5-hydroxy-1-methylhydantoin; NZ-419), against cellular damage of kidney tubules. Ienaga K, Park CH, Yokozawa T.Exp Toxicol Pathol. 2013 Jul;65(5):559-66. doi: 10.1016/j.etp.2012.05.001. Epub 2012 Jun 29. PMID: 22749566 </br>3:Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Ienaga K, Yokozawa T.Drug Discov Ther. 2011 Aug;5(4):162-75. PMID: 22466296 Free Article</br>4:Serum accumulation of a creatinine oxidative metabolite (NZ-419: 5-hydroxy-1- methylhydatoin) as an intrinsic antioxidant in diabetic patients with or without chronic kidney disease. Hasegawa G, Nakano K, Ienaga K.Clin Nephrol. 2011 Oct;76(4):284-9. PMID: 21955863 </br>5:Treatment with NZ-419 (5-Hydroxy-1-methylimidazoline-2,4-dione), a novel intrinsic antioxidant, against the progression of chronic kidney disease at stages 3 and 4 in rats. Ienaga K, Yokozawa T.Biol Pharm Bull. 2010;33(5):809-15. PMID: 20460759 Free Article</br>6:First indications demonstrating the preventive effects of NZ-419, a novel intrinsic antioxidant, on the initiation and/or progression of chronic renal failure in rats. Ienaga K, Mikami H, Yokozawa T.Biol Pharm Bull. 2009 Jul;32(7):1204-8. PMID: 19571386 Free Article |
